KCT0003990已完成未知
Blastic plasmacytoid dendritic cell neoplasm in Korean population: A multicenter study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Eligibility Criteria
- •1. Patients = 18 years
- •2. Pathologically confirmed diagnosis by tissue or bone marrow at each center with
- •- Blastic plasmacytoid dendritic cell neoplasm
- •- Blastic NK-cell lymphoma
- •- Agranular CD4+ natural killer cell leukaemia
- •- Blastic natural killer leukaemia/lymphoma
- •- Agranular CD4+CD56+ haematodermic
- •neoplasm/tumour
- •3. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303
排除标准
- •< Exclusion criteria >
- •1. Acute myeloid leukemia
- •2. Acute lymphoblastic leukemia
- •3. Mixed phenotype acute leukemia
- •4. Any type of B- or T-/NK/T-cell lymphomas
- •5. Expression of lineage-specific markers for
- •B cells (CD20, CD79a)
- •T cells (CD3)
- •Myeloid cells (myeloperoxidase)
- •Monocytes (CD11c, CD163, lysozyme).
研究者
相似试验
招募中
不适用
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International RegistryBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)NCT05430971Immune Oncology Research Institute200
已完成
不适用
Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.Blastic Plasmacytoid Dendritic Cell NeoplasmNCT03974971Samsung Medical Center36
已完成
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic disease (REACtiVe-2 Trial)NL-OMON52234Erasmus MC, Universitair Medisch Centrum Rotterdam30
招募中
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic diseaseNL-OMON27591Department of Pulmonary Medicine, Erasmus MC18
已完成
不适用
Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)Blastic Plasmacytoid Dendritic Cell NeoplasmHematological MalignanciesNCT02859623Centre Hospitalier Universitaire de Besancon86